Seeking Alpha

Pfizer Inc. (PFE)

  • Jan. 30, 2012, 5:30 PM
    Notable earnings before Tuesday's open: ADM, ARMH, AVY, BIID, CE, CIT, DHR, ETR, HP, ITW, LLY, MAT, MHP, MPC, NRGY, PCAR, PFE, TLAB, TYC, UPS, VLO, WDR, X, XOM
    | Jan. 30, 2012, 5:30 PM | Comment!
  • Jan. 30, 2012, 3:15 PM
    Pfizer (PFE +0.1%) says it's preparing to seek U.S. regulatory approval to sell a new menopause drug, Aprela, as a potential alternative to the company's older hormone-replacement therapies, which have been tied in the past to safety risks.
    | Jan. 30, 2012, 3:15 PM | Comment!
  • Jan. 30, 2012, 8:59 AM
    Pharmacy benefit manager Express Scripts (ESRX) will soon raise out-of-pocket costs for customers using Pfizer's (PFE) cholesterol-lowering drug Lipitor, following the introduction of generic versions late last year. The move underscores the drug maker's challenge of keeping sales high in the face of generic competition. ESRX +1.2%, PFE -0.3% premarket.
    | Jan. 30, 2012, 8:59 AM | Comment!
  • Jan. 27, 2012, 12:46 PM
    The FDA approves Pfizer's (PFE -0.2%) Inlyta for patients with advanced kidney cancer. The action could dent sales at Onyx Pharmaceuticals (ONXX -1.4%) if Pfizer's treatment is deemed more effective than its own version.
    | Jan. 27, 2012, 12:46 PM | Comment!
  • Jan. 18, 2012, 7:58 AM
    Shares of Jazz Pharmaceuticals (JAZZ) are halted pending a news announcement. Trader chatter is centering on a potential buyout by Pfizer (PFE).
    | Jan. 18, 2012, 7:58 AM | Comment!
  • Jan. 17, 2012, 7:31 AM
    Medivation (MDVN) and Pfizer (PFE) announce that their jointly-developed Dimebon treatment of Alzheimer's failed to achieve statistically significant results for endpoints in a Phase III trial. Due to the development, the firms say they'll discontinue developing the drug. Shares of MDVN -4.9% premarket, PFE +0.3%.
    | Jan. 17, 2012, 7:31 AM | Comment!
  • Jan. 12, 2012, 5:03 PM
    Nestle (NSRGY.PK) and Danone (DANOY.PK) have made initial bids for Pfizer's (PFE) baby-formula division, reports Bloomberg. However, sources claim Pfizer may still opt to spin off the business rather than sell it. It was claimed in July that the unit could fetch as much as $10.5B. Yesterday, Abbott Laboratories (ABT) said it isn't interested in making a bid.
    | Jan. 12, 2012, 5:03 PM | Comment!
  • Jan. 10, 2012, 2:49 PM
    Pfizer's (PFE +0.5%) Lipitor cholesterol drug is holding onto ~37%-38% of the overall U.S. market as it competes with generic versions, CEO Ian Read says, "basically where we expected to be." But he says it would be difficult for Pfizer to hold more than its current share, as some patients are encountering resistance at pharmacies wanting to fill prescriptions with a generic.
    | Jan. 10, 2012, 2:49 PM | Comment!
  • Jan. 9, 2012, 10:48 AM
    Evidence the eurozone crisis is turning the world upside down: with EU banks not lending to each other, cash rich multinationals, such as J&J (JNJ), Pfizer (PFE) and Peugeot (PEUGY.PK), are stepping into the gap and are lending to banks via the repo market, Reuters reports. In one key area, corporations account for 25% of the deals.
    | Jan. 9, 2012, 10:48 AM | 2 Comments
  • Jan. 3, 2012, 10:29 AM
    The FDA fast tracks a pneumonia vaccine from Pfizer (PFE +1.4%) for use by adults aged 50 and older, drastically extending the reach for the drug beyond just use in children. Prevnar already stands as one of Pfizer's fastest-growing drugs since launching in 2010, topping the $1B sales mark in Q3 last year.
    | Jan. 3, 2012, 10:29 AM | Comment!
  • Dec. 30, 2011, 8:05 PM
    Top five Dow gainers of 2011: MCD +31%, IBM +27%, PFE +24%, HD +20%, KFT +20%. Top S&P gainers: COG +103%, EP +92%, ISRG +81%, MA +69%, BIIB +65%. Top Nasdaq gainers: VRUS +469%, EGAN +412%, SIMO +392%, INHX +308%, TSTF +276%.
    | Dec. 30, 2011, 8:05 PM | 1 Comment
  • Dec. 21, 2011, 11:16 AM
    Among the stocks making new 52 week highs as year end approaches are faithful big-caps across a number of industries - Wal-Mart (WMT), Pfizer (PFE), Verizon (VZ), and McDonald's (MCD). All yield more than the 10-year Treasury and likely have more adaptive managements than that in D.C. What's not to like?
    | Dec. 21, 2011, 11:16 AM | 8 Comments
  • Dec. 16, 2011, 8:56 AM
    Pfizer (PFE) says a Phase III study of its Lyrica drug capsules for restless legs syndrome met each of its three co-primary endpoints, showing "significant" benefit vs. a placebo and pramipexole. Pfizer says it will continue to analyze the results. PFE +1.1% premarket. (PR)
    | Dec. 16, 2011, 8:56 AM | Comment!
  • Dec. 14, 2011, 7:50 AM
    Fitch is establishing a negative 2012 outlook for pharmaceutical companies, arguing soft demand, patent expirations, and government spending cuts will take a toll on the industry; the patent expirations (I, II, III) are seen affecting LLY, BMY, and PFE the most. Fitch also sees pharmas responding to these challenges by stepping up their M&A activity.
    | Dec. 14, 2011, 7:50 AM | Comment!
  • Dec. 13, 2011, 8:13 AM
    Pfizer's (PFE) Lipitor cholesterol pill lost about 15% of its market share in the first few days after its patent protection ended on November 30. Meanwhile, the pharmaceutical manufacturer yesterday named CEO Ian Read as Chairman to replace George Lorch, who becomes Lead Independent Director.
    | Dec. 13, 2011, 8:13 AM | Comment!
  • Dec. 12, 2011, 11:46 AM
    Pfizer (PFE -0.9%) announces a 10% dividend increase, bringing the annual amount to $0.88, a yield of 4.3%. The board also approves a new $10B share repurchase program to be tacked onto what's left of the existing authorization. (PR)
    | Dec. 12, 2011, 11:46 AM | Comment!
Company Description
Pfizer Inc is a research-based biopharmaceutical company. The Company has five operating segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health; and Consumer Healthcare.